Klow Peptide Kpv
KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment derived from alpha-melanocyte-stimulating hormone that demonstrates potent anti-inflammatory potential in preclinical research models. Investigators evaluate KPV to study cellular signaling cascades, mucosal immunity, and intestinal barrier restoration without triggering melanogenic receptor activity. PX1 Research supplies high-purity KPV tripeptide reagents engineered specifically for rigorous in vitro and animal research protocols.
Quick answer
KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment derived from alpha-melanocyte-stimulating hormone that demonstrates potent anti-inflammatory potential in preclinical research models. Investigators evaluate KPV to study cellular signaling cascades, mucosal immunity, and intestinal barrier restoration without triggering melanogenic receptor activity. PX1 Research supplies high-purity KPV tripeptide reagents engineered specifically for rigorous in vitro and animal research protocols.
Key takeaways
- Klow peptide [KPV](/research-peptides/kpv) is a synthetic tripeptide comprising the amino acid sequence Lysine-Proline-Valine (Lys-Pro-Val).
- At the structural level, [KPV](/research-peptides/kpv) consists of three L-amino acids joined by standard peptide bonds: L-lysine, L-proline, and L-valine.
- The primary mechanism attributed to [KPV](/research-peptides/kpv) in the scientific literature is its capacity to downregulate nuclear factor kappa B (NF-κB) nuclear translocation.
- A major focal point of [KPV](/research-peptides/kpv) investigation centers on gastrointestinal pathophysiology.
Direct Overview: What is Klow Peptide KPV?
Klow peptide KPV is a synthetic tripeptide comprising the amino acid sequence Lysine-Proline-Valine (Lys-Pro-Val). Derived from the C-terminus of alpha-melanocyte-stimulating hormone (α-MSH), it functions as an anti-inflammatory research compound. Preclinical studies evaluate KPV for modulating inflammatory pathways, downregulating NF-κB signaling, and maintaining epithelial tissue integrity in intestinal barrier and colitis models.
Unlike full-length melanocortin peptides, KPV retains the core immunomodulatory signaling properties of α-MSH while omitting the sequence components responsible for pigmentary stimulation via the melanocortin-1 receptor (MC1R). This selectivity makes the KPV tripeptide reagent a valuable chemical tool for isolated inflammatory research where pigmentary side effects or receptor cross-talk would obscure experimental endpoints.
Biochemical Identity and Structural Features of KPV
At the structural level, KPV consists of three L-amino acids joined by standard peptide bonds: L-lysine, L-proline, and L-valine. It possesses a molecular formula of C16H30N4O4 and a defined molecular mass of approximately 342.43 g/mol. The inclusion of proline introduces a rigid turn in the peptide backbone, which is hypothesized to protect the molecule against rapid enzymatic degradation by circulating carboxypeptidases in preclinical models.
In chemical assays, KPV exhibits high water solubility and stability across a physiological pH range. Researchers investigating cytokine signaling pathways frequently select KPV due to its low steric molecular profile, allowing efficient cellular membrane interaction and transport through specialized epithelial uptake systems.
Anti-Inflammatory Mechanisms of Action in Preclinical Models
The primary mechanism attributed to KPV in the scientific literature is its capacity to downregulate nuclear factor kappa B (NF-κB) nuclear translocation. NF-κB is a master transcription factor governing the expression of pro-inflammatory mediators. In vitro data indicate that KPV enters inflammatory cells and attenuates the phosphorylation and degradation of IκBα, thereby locking NF-κB in its inactive cytoplasmic state.
By interrupting NF-κB activation, preclinical assays demonstrate a downstream reduction in the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Furthermore, animal studies show that KPV suppresses inducible nitric oxide synthase (iNOS) expression, mitigating oxidative stress within inflamed epithelial tissues.
Intestinal Barrier Function and Colitis Research
A major focal point of KPV investigation centers on gastrointestinal pathophysiology. In rodent models of inflammatory bowel disease (IBD), such as dextran sulfate sodium (DSS)-induced colitis, administration of KPV significantly reduces mucosal damage, neutrophil infiltration, and histological inflammation scores. The peptide enters enterocytes via Peptide Transporter 1 (PepT1), an apical membrane transporter whose expression is upregulated during intestinal inflammation.
Once internalized via PepT1, KPV acts directly within intestinal epithelial cells to restore tight junction proteins, including Zonula Occludens-1 (ZO-1) and occludin. In vitro cell monolayer experiments confirm that KPV treatment preserves transepithelial electrical resistance (TEER) following exposure to inflammatory challenges, highlighting its utility in barrier permeability research.
Antimicrobial and Epithelial Homeostasis Properties
Beyond direct immunomodulation, preclinical studies suggest that KPV exerts endogenous antimicrobial activity against select opportunistic pathogens, most notably *Candida albicans* and *Staphylococcus aureus*. Unlike conventional broad-spectrum microbicides, KPV appears to disrupt fungal filamentation and bacterial cell wall integrity at micromolar concentrations while maintaining host cell viability.
This dual action—simultaneously suppressing hyper-inflammatory host responses while inhibiting microbial overgrowth—makes KPV a unique candidate for studying complex mucosal barrier dynamics. Researchers often utilize KPV in co-culture models to observe how host cells balance immune clearance against collateral tissue destruction during localized infection.
Comparative Analysis: KPV vs. Other Mucosal Research Peptides
When designing gastrointestinal or tissue repair research protocols, investigators frequently compare KPV with other established tissue-protective signaling compounds. Selecting the appropriate compound depends on whether the primary endpoint involves cytokine regulation, tight junction assembly, or broad antimicrobial host defense.
For example, while KPV directly targets intracellular NF-κB translocation via PepT1 transport, BPC-157 operates primarily through angiogenic growth factor modulation and nitric oxide signaling pathways. Conversely, Larazotide acetate functions as a dedicated tight junction regulator that inhibits zonulin-mediated pathway opening without direct antimicrobial activity. For studies requiring potent, direct pathogen neutralization alongside immune modulation, researchers may contrast KPV with the human cathelicidin fragment LL-37. Exploring our complete catalog of research peptides allows lab managers to configure multi-targeted experimental arms.
Laboratory Reconstitution and Handling Protocols
To maintain chemical integrity and experimental reproducibility, KPV lyophilisate must be stored at -20°C or lower upon receipt. Prior to opening the vial, allow the container to equilibrate to room temperature to prevent condensation of atmospheric moisture onto the hygroscopic peptide powder.
Reconstitute KPV using sterile, molecular-biology-grade water or phosphate-buffered saline (PBS, pH 7.4). Swirl gently to dissolve; avoid vigorous vortexing or mechanical agitation, which can induce peptide aggregation. Once reconstituted, stock solutions should be divided into single-use experimental aliquots and frozen at -80°C. Repeated freeze-thaw cycles must be strictly avoided to prevent peptide backbone cleavage.
Quality Assurance and Supplier Verification Standards
Reliable research outcomes require absolute verification of compound purity, identity, and cleanliness. When sourcing KPV for preclinical trials, laboratory managers must demand analytical verification beyond simple manufacturer self-certification. Substandard peptides containing truncated sequences, residual TFA salts, or endotoxin contamination yield false positives and non-reproducible cellular assays.
PX1 Research enforces rigorous batch validation protocols. Every lot of KPV undergoes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to guarantee a purity threshold of ≥98%. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms exact molecular weight, while Limulus Amebocyte Lysate (LAL) assays ensure endotoxin levels remain strictly under <0.01 EU/mg. All analytical testing is performed in accredited, independent ISO 17025 facilities.
Sourcing KPV Tripeptide Reagents from PX1 Research
PX1 Research serves as a trusted primary vendor for academic institutions, biotechnology firms, and contract research organizations across the United States. All peptides are synthesized in state-of-the-art, GMP-compliant facilities within the USA, ensuring absolute lot-to-lot traceability and chemical consistency.
Orders placed before 2:00 PM EST ship same-day from our dual logistics hubs located in California and Arizona, minimizing transit times and thermal exposure. Researchers requiring large-scale reagent quantities or customized batch synthesis can access our specialized wholesale lab program or review underlying study documentation within the PX1 research library.
Frequently Asked Questions
What is the exact amino acid sequence of Klow peptide KPV?
KPV is a tripeptide with the chemical sequence Lysine-Proline-Valine (Lys-Pro-Val), derived from the carboxy-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH).
Does KPV require specialized transporters for intracellular entry?
Yes, preclinical literature demonstrates that KPV is actively transported across cell membranes, particularly intestinal enterocytes, via Peptide Transporter 1 (PepT1).
How does KPV differ from full-length α-MSH in research applications?
While α-MSH activates multiple melanocortin receptors (MC1R through MC5R) leading to pigmentary changes and systemic endocrine effects, KPV acts selectively on anti-inflammatory pathways like NF-κB without stimulating MC1R pigmentary pathways.
What purity level is required for KPV in in vitro inflammatory assays?
In vitro and cellular assays require a minimum purity of 98% determined by RP-HPLC to prevent background cellular toxicity or confounding inflammatory signaling caused by peptide impurities.
How should reconstituted KPV solutions be stored?
Reconstituted KPV stock solutions should be aliquoted into single-use volumes and stored at -80°C. Avoid repeated freeze-thaw cycles, which compromise structural stability.
What are the standard endotoxin specifications for PX1 Research KPV?
PX1 Research subjects every KPV lot to LAL assay testing, certifying endotoxin levels below 0.01 EU/mg to prevent endotoxin-induced toll-like receptor activation in research models.
Is KPV suitable for human administration or clinical therapy?
No. KPV provided by PX1 Research is strictly designated as a research chemical for laboratory, in vitro, and preclinical research use only. It is not approved for human or animal clinical consumption.
Where is PX1 Research KPV manufactured and shipped from?
PX1 Research compounds are synthesized in USA-based, GMP-compliant facilities and dispatched same-day from fulfillment centers in California and Arizona.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.